Cell Therapy Technologies Market

Cell Therapy Technologies Market Outlook (2023 to 2033)

Newly-released cell therapy technologies market analysis report by Fact.MR reveals that global sales in 2022 were held at US$ 4.5 Billion. With 14.4% projected growth from 2023 to 2033, the market is expected to reach a valuation of US$ 19.6 Billion by the end of the forecast period. Media, Sera, and Reagents is expected to be the highest revenue-generating type, projected to grow at a CAGR of over 14.2% from 2023 to 2033.

Attributes	Details
Global Cell Therapy Technologies Market Size (2022)	US$ 4.5 Billion
Global Cell Therapy Technologies Market Size (2033)	US$ 19.6 Billion
Global Cell Therapy Technologies Market CAGR (2023 to 2033)	14.4%
U.S. Cell Therapy Technologies Market CAGR (2023 to 2033)	14.2%
Key Companies Covered	Thermo Fischer Scientific, Inc. Merck KGaA Danaher Corporation Lonza Group Sartorius Terumo BCT Becton, Deckinson and Company Fresenius SE & Co. KGaA Avantor Inc. Bio-Techne Corporation Corning Incorporated FUJIFILM Irvine Scientific MaxCyte Inc. RoosterBio Inc.

Revenue of Cell Therapy Technologies Market from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033

As per the research of the cell therapy technologies market by Fact.MR - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 12.2% CAGR. With an absolute dollar opportunity of US$ 14.5 Billion, the market is projected to reach a valuation of US$ 19.6 Billion by 2033.

Which Key Drivers are Influencing the Market Expansion?

Key drivers influencing the market expansion include Increasing investment in cell therapy, growing demand for personalized medicine, rising healthcare expenditure, advancement in Technology, growing populations of infectious diseases and cancer, government funding, and increasing investment in R&D.

Cell therapy technologies involve the use of living cells, either from the patient or from a donor, to treat or cure diseases. The growing cases of chronic diseases such as cancer, autoimmune disorders, and cardiovascular diseases are increasing globally. Cell therapy technologies help in the treatment of these diseases, which is driving the demand for these therapies.

In 2019, According to the American cancer society, an estimated 1.76 million new cases of cancer were diagnosed in the United States. Breast cancer and lung cancer were the leading causes of death accounting for over 271 thousand cases diagnosed with breast cancer and about 228 thousand cases diagnosed with lung cancer. Cell therapy technologies offer a promising treatment option for these diseases, which is driving the demand for these therapies.

The most common form of blood cancer that can affect people of any age is leukemia. The most prevalent form of leukemia in adults is chronic lymphocytic leukemia (CLL). By 2020, there was an increase of about 3.7 million new instances of blood cancer in the United States while about 60 thousand new cases and 23 thousand deaths were reported from leukemia. With the increasing population of cancer, there is increasing demand for cell therapies which is expected to drive the market.

Region-Wise Analysis :

Which Region is Projected to Offer Significant growth in Market?

North America is a prominent shareholder in the market with a market size of US$ 1.1 Billion in 2022 and is estimated to reach US$ 1.3 Billion in 2023. It is projected that the region will have a market worth US$ 5.1 Billion by 2033.

In 2019, According to the Canadian Cancer Society, lung cancer was the most commonly diagnosed cancer in Canada. About 29 thousand cases were diagnosed and around 21 thousand deaths were reported in Canada in 2019. The numbers of lung cancer cases are increasing year over year which can influence the increasing demand for the cell therapy technologies.

Country-Wise Analysis :

United States Cell Therapy Technologies Market Analysis :

The market in the United States is expected to grow to be worth US$ 4.4 Billion by 2033, with an absolute dollar growth of US$ 3.3 Billion from 2023 to 2033. The market in the United States has grown at a CAGR of 11.7% from 2018 to 2022 and is expected to grow at a CAGR of 14.2% from the year 2023 to 2033.

The U.S. Food and Drug Administration (FDA) has also taken steps to encourage the development of cell therapy treatments. In 2017, the FDA launched its Regenerative Medicine Advanced Therapy (RMAT) designation program, which provides advancement in technology and review for regenerative medicine products, including cell therapy. The government has established several initiatives to promote the development of cell therapy and provides funding for the development of new medical treatments including cell therapy.

United Kingdom Cell Therapy Technologies Market Analysis :

The market in the United Kingdom is expected to grow to be worth US$ 888.1 million by 2033, with an absolute dollar growth of US$ 639.4 million. The market in the United Kingdom has grown at a CAGR of 10.7% from 2018 to 2022 and is expected to grow at a CAGR of 13.6% from 2023 to 2033.

According to research, in 2020, about 145 thousand people were living with Parkinson’s disease and over 4 thousand cases died in the United Kingdom. Cell therapy plays a significant role in the prevention and treatment of Parkinson’s disease. Due to the increasing population of various diseases, the demand for cell therapy technologies is also on rise.

China Cell Therapy Technologies Market Analysis :

In China, the market is expected to grow to be worth US$ 3.2 billion with an absolute dollar growth of US$ 2.4 million till 2033. The market in China has grown at a CAGR of 11.4% from 2018 to 2022 and is expected to grow at a CAGR of 13.9% from 2023 to 2033.

According to the WHO, in 2019, China was significantly affected by Ischemic heart disease there were over 6.5 million cases diagnosed and about 2.7 million people died due to this disease.

In addition to addressing the molecular mechanisms of cardiac conditioning, stem cell therapy will make it possible to develop new treatments for ischemic heart disease. Examples of such therapies include the potential use of human mesenchymal stem cells and induced pluripotent stem cells. These therapies help in the prevention and treatment of Ischemic heart disease.

Japan Cell Therapy Technologies Market Analysis :

In Japan, the market is expected to grow to be worth US$ 788.9 million with an absolute dollar growth of US$ 539.1 Million. The market in Japan has grown at a CAGR of 9% from 2018 to 2022 and is expected to grow at a CAGR of 12.2% from the year 2023 to 2033.

In 2019, the Japanese government announced a US$ 900 million investment to fund research and development in regenerative medicine, including cell therapy. Furthermore, the Japanese government has established several initiatives to promote the development of regenerative medicine and cell therapy. Due to an increase in investment and government funding cell therapy technologies has also been rising.

South Korea Cell Therapy Technologies Market Analysis :

The market in South Korea is expected to grow to be worth US$ 752.6 million by 2033, with an absolute dollar growth of US$ 497.6 million. The market in the country has grown at a CAGR of 8.1% from 2018 to 2022 and is expected to grow at a CAGR of 11.4% from 2023 to 2033.

In 2019, breast cancer was the most common type of cancer in South Korea. Around 25 thousand new cases were diagnosed. Due to the increase in various types of cancer, advanced cell therapy techniques are widely used.

In 2021, the Ministry of Food and Drug Safety of Korea approved a clinical-stage biotech developing next-generation CAR-T cell therapy for the treatment of various types of cancer. It influences the demand for cell therapy technologies in the upcoming years.

Category-Wise Insights

Which Product Type in of Cell Therapy Technologies is Projected to Witness Significant Growth?

Media, Sera, and Reagents is projected to witness the fastest growth with a CAGR of 12.1% from 2018 to 2022 and is expected to grow at a CAGR of 14.2% from 2023 to 2033.

Media, sera, and reagents play a crucial role in maintaining healthy and viable cells in culture, enabling biopharmaceutical and biotechnology companies to develop and manufacture advanced therapies. The quality and consistency of these components are critical to ensure reproducibility and consistency in cell-based products.

Through Which End User Cell Therapy Technologies is Projected to Grow at a Significant Pace?

The market through biopharmaceutical and biotechnology companies is projected to witness the significant growth with a CAGR of 11.8% from 2018 to 2022 and is expected to grow at a CAGR of 13.9% from 2023 to 2033.

Cell therapy technology is used by biopharmaceutical and biotechnology companies to develop and manufacture advanced therapies. These companies use cell therapy technology to develop cell-based products that can be used to treat a wide range of diseases, including cancer, genetic disorders, and autoimmune diseases.

One of the key applications of cell therapy technology in biopharmaceutical and biotechnology companies is in the development of CAR-T cell therapies. CAR-T cell therapies are a type of immunotherapy that uses a patient's immune cells to target and kill cancer cells. Biopharmaceutical and biotechnology companies use cell therapy technology to isolate and genetically modify T cells from a patient's blood, creating CAR-T cells that can recognize and destroy cancer cells.

Competitive Analysis :

Key players in the market are Thermo Fischer Scientific, Inc., Merck KGaA, Danaher Corporation, Lonza Group, Sartorius, Terumo BCT, Becton Dickinson and Company, Fresenius SE & Co. KGaA, Avantor Inc., Bio-Techne Corporation, Corning Incorporated, FUJIFILM Irvine Scientific, MaxCyte Inc., and RoosterBio Inc.

The market is constantly evolving with new developments and innovations. These advancements are driving the growth of the market and improving the efficacy and safety of cell therapies.

A few of the recent developments in the market are :

• In January 2022, PeproTech, a privately held bioscience reagents provider was acquired by Thermo Fisher Scientific for US$ 1.85 billion. The acquisition was targeted for increasing its capabilities in the high growth cell and gene therapy market.
• In March 2019, Thermo Fisher Scientific acquired Brammer Bio specializing in viral vector manufacturing for gene and cell therapies, for the expansion of its cell therapy manufacturing capabilities.

Segmentation of the Cell Therapy Technologies Market :

• By Product :

  • Media, Sera, and Reagents
  • Cell Engineering Products
  • Cell Culture Vessels
  • Cell Therapy Equipment
  • Cell Processing Equipment
  • Single-use Equipment
  • Systems and Software

• By Process :

  • Cell Processing
  • Cell Preservation, Distribution, and Handling
  • Process Monitoring and Quality Control

• By Cell Type :

  • T-cells
  • Stem Cells
  • Other Cells

• By End User :

  • Biopharmaceutical & Biotechnology Companies
  • CROs and CMOs
  • Research Institutes and Cell Banks

• By Region :

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa